Skip to content

Phase I/II study of stereotactic body radiotherapy boost in patients with cervical cancer unable to brachytherapy

Phase I/II study of stereotactic body radiotherapy boost in patients with cervical cancer unable to brachytherapy

Status
Active, not recruiting
Phases
Phase 2
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2400092058
Enrollment
Unknown
Registered
2024-11-08
Start date
2024-11-15
Completion date
Unknown
Last updated
2024-11-11

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cervical cancer

Interventions

Interventions group:stereotactic body radiotherapy, SBRT instead of brachytherapy

Sponsors

Peking University First Hospital
Lead Sponsor

Eligibility

Sex/Gender
Female
Age
18 Years to No maximum

Inclusion criteria

Inclusion criteria: ? Age =18 years old; KPS score =70; ? squamous cell carcinoma, adenocarcinoma or adenosquamous carcinoma confirmed by pathology; ? FIGO stage ?~?; ? MRI examination can be performed to evaluate the tumor before, during and after treatment ; ? at least 50% of tumor regression after pelvic external irradiation; ? patients who are unsuitable or unwilling to receive a boost by brachytherapy ? patients willing to accept long-term follow-up.

Exclusion criteria

Exclusion criteria: ?KPS score < 70; ? No pathological examination results; ? patients with previous pelvic radiotherapy; ? patients could not undergo MRI because of intrauterine device (IUD) ? Tumor regression was less than 50%, the residual tumor was large after pelvic external irradiation.

Design outcomes

Primary

MeasureTime frame
2-year local tumor control rate;

Secondary

MeasureTime frame
acute and late toxicity of radiotherapy;2-year overall survival ;

Countries

China

Contacts

Public ContactLi Xiaomei

Peking University First Hospital

13439332195@163.com+86 134 3933 2195

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026